Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01422408 | Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy | completed | Phase 2 | 34 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00331552 | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Jul 26, 2017 |
| clinicaltrials |
| NCT00054132 | Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00003199 | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01639248 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | completed | Phase 2 | 41 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2017 | clinicaltrials |
| NCT01965522 | Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer(MELO-D) | completed | Phase 2 | 100 | Juravinski Cancer CenterOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00165243 | Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT00791037 | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT02077569 | AKT Inhibitor in Oestrogen Positive Breast Cancer(STAKT) | completed | Phase 2 | 48 | University of NottinghamOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00635050 | Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | completed | Phase 2 | 32 | University of Alabama at BirminghamOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00244881 | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT00952731 | 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ | completed | Phase 2 | 27 | Northwestern UniversityOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT00951054 | A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 61 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Feb 16, 2015 | clinicaltrials |
| NCT02190227 | RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment | completed | Phase 2 | 30 | Jewish General HospitalOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT00100750 | Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00068588 | GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2014 | clinicaltrials |
| NCT00258349 | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00077376 | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00119262 | Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | completed | Phase 2 | 226 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00559507 | Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2014 | clinicaltrials |
| NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy(DAFNE) | completed | Phase 2 | 65 | GBG Forschungs GmbHOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00006228 | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00049114 | Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00098605 | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00429182 | Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | completed | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00005817 | Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00024154 | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098397 | FR901228 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00045188 | Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00017394 | Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00586326 | MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ(DCIS) | completed | Phase 2 | 133 | Hologic, Inc.INDUSTRY | 1 | Nov 6, 2012 | clinicaltrials |
| NCT00031278 | Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 12 | PfizerINDUSTRY | 1 | May 30, 2011 | clinicaltrials |
| NCT00106002 | Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer | completed | Phase 2 | 37 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 1, 2009 | clinicaltrials |
| NCT00043394 | CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer | completed | Phase 2 | 16 | PfizerINDUSTRY | 1 | Mar 12, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2017source: clinicaltrials